Bain Capital Life Sciences Investors, LLC Long-Term Concentrated

CIK: 0001703031 · Show all filings

Period: Q4 2019 (← Previous) (Next →)

Filing Date: Feb 14, 2020

Total Value ($000): $670,536 (100.0% shares, 0.0% debt)

Holdings (10)

— SPRINGWORKS THERAPEUTICS INC 41.8%
Value ($000) $280,258 Shares 7,281,307 Est. Cost $21.68 Unrealized —
— CONSTELLATION PHARMACEUTICALS INC. 19.8%
Value ($000) $133,016 Shares 2,823,529 Est. Cost $47.11 Unrealized —
— DICERNA PHARMACEUTICALS INC 13.4%
Value ($000) $89,888 Shares 4,080,237 Est. Cost $9.03 Unrealized —
— DYNAVAX TECHNOLOGIES CORP. 7.2%
Value ($000) $48,347 Shares 8,452,235 Est. Cost $3.58 Unrealized —
REPL REPLIMUNE GROUP INC 6.1%
Value ($000) $40,739 Shares 2,838,968 Est. Cost $17.53 Unrealized -17.8%
SVRA SAVARA INC 3.4%
Value ($000) $22,976 Shares 5,128,593 Est. Cost $1.20 Unrealized 0.0%
— X4 PHARMACEUTICALS INC 2.6%
Value ($000) $17,639 Shares 1,648,485 Est. Cost $10.70 Unrealized —
— SOLID BIOSCIENCES INC 2.6%
Value ($000) $17,227 Shares 3,871,164 Est. Cost $8.88 Unrealized —
— MARINUS PHARMACEUTICALS INC 1.9%
Value ($000) $12,836 Shares 5,942,735 Est. Cost $6.30 Unrealized —
— APTINYX INC 1.1%
Value ($000) $7,610 Shares 2,225,092 Est. Cost $24.17 Unrealized —